N/A N=32

Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors

Skin Toxicities

Bottom Line

View on ClinicalTrials.gov: NCT01015326 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2013

Primary outcome: Primary: Qualitative Data From Patients and Experts to Measure Anti-EGFR Therapy-specific Health-related Quality of Life (HRQL) — 2.70; 2.41; 2.70; 2.29 units on a scale

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Questionnaire (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Northwestern University
Primary completion: Nov 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY Qualitative Data From Patients and Experts to Measure Anti-EGFR Therapy-specific Health-related Quality of Life (HRQL)	2.70; 2.41; 2.70; 2.29; 1.90; 2.14	—

Summary

Epidermal Growth Factor Receptor Inhibitors (EGFRI) are associated with skin toxicities. Clinical experience suggests that skin toxicities interfere with health related quality of life (HRQL) and may interfere with treatment adherence. No systematic investigations of EGFRI-associated dermatologic toxicities and impact on HRQL have been reported. No patient-reported outcome measures exist to capture the unique concerns of oncology patients who experience EGFRI-associated dermatologic toxicities. The purpose of this study is to develop a patient-reported outcomes measure to assess dermatologic-related symptoms burden and health-related quality of life among patients receiving an EGFRI, and to develop a grading system for EGFRI-associated dermatologic toxicities.

Eligibility Criteria

Inclusion Criteria

Undergoing anti-EGFR cancer therapy
Over 18 years old

Exclusion Criteria

Unable to complete the questionnaire
Unable to follow instructions or give consent

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01015326). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.